StoneX Group’s Pfizer PFE Stock Holding History

StoneX Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$806K	Buy	33,470 +5,064	+18%	+$132K	0.03%	410
2026 Q1	$797K	Sell	28,406 -8,778	-24%	-$234K	0.04%	307
2025 Q4	$926K	Sell	37,184 -2,770	-7%	-$69.9K	0.04%	369
2025 Q3	$1.02M	Sell	39,954 -1,107	-3%	-$27.3K	0.04%	354
2025 Q2	$995K	Sell	41,061 -50,462	-55%	-$1.18M	0.05%	329
2025 Q1	$2.32M	Buy	91,523 +15,127	+20%	+$396K	0.13%	148
2024 Q4	$2.03M	Buy	76,396 +23,415	+44%	+$635K	0.11%	167
2024 Q3	$1.53M	Sell	52,981 -5,650	-10%	-$165K	0.11%	153
2024 Q2	$1.64M	Buy	58,631 +9,827	+20%	+$271K	0.13%	137
2024 Q1	$1.35M	Sell	48,804 -18,836	-28%	-$523K	0.12%	158
2023 Q4	$1.95M	Sell	67,640 -3,949	-6%	-$119K	0.19%	98
2023 Q3	$2.37M	Buy	71,589 +16,812	+31%	+$595K	0.26%	83
2023 Q2	$2.01M	Buy	54,777 +2,838	+5%	+$110K	0.21%	99
2023 Q1	$2.12M	Buy	51,939 +6,741	+15%	+$291K	0.23%	87
2022 Q4	$2.32M	Buy	45,198 +5,196	+13%	+$249K	0.27%	70
2022 Q3	$1.75M	Buy	40,002 +2,960	+8%	+$144K	0.24%	86
2022 Q2	$1.94M	Sell	37,042 -1,202	-3%	-$61.3K	0.24%	85
2022 Q1	$1.98M	Buy	38,244 +3,536	+10%	+$183K	0.16%	129
2021 Q4	$2.05M	Buy	34,708 +10,387	+43%	+$515K	0.24%	88
2021 Q3	$1.05M	Sell	24,321 -3,260	-12%	-$144K	0.15%	147
2021 Q2	$1.08M	Buy	27,581 +3,051	+12%	+$119K	0.16%	138
2021 Q1	$889K	Buy	24,530 +3,006	+14%	+$107K	0.16%	133
2020 Q4	$792K	Buy	21,524 +4,372	+25%	+$160K	0.17%	123
2020 Q3	$597K	Buy	17,152 +3,544	+26%	+$124K	0.19%	130
2020 Q2	$422K	Sell	13,608 -994	-7%	-$33.8K	0.16%	169
2020 Q1	$452K	Sell	14,602 -1,183	-7%	-$40.3K	0.24%	118
2019 Q4	$587K	Buy	15,785 +2,869	+22%	+$102K	0.24%	125
2019 Q3	$440K	Buy	12,916 +1,174	+10%	+$42.7K	0.27%	126
2019 Q2	$483K	Buy	11,742 +276	+2%	+$11K	0.31%	100
2019 Q1	$462K	Buy	11,466 +2,178	+23%	+$87.2K	0.35%	94
2018 Q4	$385K	Buy	9,288 +1,623	+21%	+$67.4K	0.37%	92
2018 Q3	$320K	Sell	7,665 -224	-3%	-$8.62K	0.24%	155
2018 Q2	$272K	Buy	7,889 +607	+8%	+$20.7K	0.23%	170
2018 Q1	$245K	Buy	7,282 +624	+9%	+$21.5K	0.23%	173
2017 Q4	$229K	Sell	6,658 -204	-3%	-$6.96K	0.24%	174
2017 Q3	$232K	Sell	6,862 -52,247	-88%	-$1.68M	0.29%	143
2017 Q2	$1.88M	Buy	59,109 +48,249	+444%	+$1.52M	0.59%	40
2017 Q1	$335K	Sell	10,860 -195	-2%	-$6.15K	0.75%	48
2016 Q4	$341K	Buy	+11,055	New	+$337K	0.6%	65

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

StoneX Group's PFE Position: Q2 2026 in Review

StoneX Group increased its Pfizer (PFE) stake by 18% in Q2 2026, buying an estimated $132K and bringing the position to 33,470 shares worth $806K. The position accounts for 0.03% of the portfolio, ranked #410.

StoneX Group first reported a position in PFE in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.37M in Q3 2023. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

StoneX Group held 33,470 shares of Pfizer worth $806K as of Q2 2026.
StoneX Group bought 5,064 Pfizer shares in Q2 2026, an estimated $132K.
Pfizer made up 0.03% of StoneX Group's portfolio in Q2 2026, its #410 holding.
StoneX Group first reported a position in Pfizer in Q4 2016 and has held it in 39 quarters since.
StoneX Group's Pfizer position peaked at $2.37M in Q3 2023.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.